

## Synvisc-One™ Fact Sheet

- Synvisc-One (a viscosupplement) is a single intra-articular injection used to decrease pain and discomfort associated with osteoarthritis of the knee for up to 6 months.<sup>1</sup>
- Synvisc-One is not a drug, therefore does not carry any of the possible gastrointestinal and cardiovascular issues associated with some oral medications.
- Viscosupplement treatments are used to restore the physiological and rheological states of the arthritic joint tissues.
- Synvisc-One is a high-molecular weight treatment comprised of Hylans (derivative of hyaluronan) that is similar to healthy young synovial fluid found in 18-27 year olds.<sup>1</sup>
- Osteoarthritis (OA) is the most common form of arthritis and affects approximately 1 in 10 Canadians.<sup>2</sup> Up to age 55, about the same percentage of men and women have osteoarthritis. After that age, women are more vulnerable.<sup>3</sup>
- Symptoms can range from very mild to very severe and can limit daily activities. Clinical evidence suggests the earlier a patient seeks treatment with viscosupplementation, the better their outcome.<sup>4</sup>
- Synvisc-One is a line extension to the growing Synvisc® family of products including: a 3 X 2mL injection indicated for OA of the knee and a 1 X 2mL injection indicated for the hip, shoulder and ankle.
- Synvisc (3 X 2mL) has treated over 5 million knees worldwide has over 10 years of clinical experience.<sup>5</sup>
- Synvisc-One is administered via 6mL intra-articular injection directly into the knee joint.
- A double-blind, randomized, placebo-controlled multi-centre clinical study of Synvisc-One demonstrated the product's efficacy and safety. The study demonstrated symptomatic pain relief with Synvisc-One for up to 6 months and was well-tolerated upon initial and repeat treatments.<sup>6</sup>

1. Synvisc-One Package Insert, 2009; Genzyme Canada Inc.
2. Vancouver Coastal Health [http://www.vch.ca/oasis/oa\\_about.htm](http://www.vch.ca/oasis/oa_about.htm)
3. Health Canada. Seniors and Aging. It's Your Health 2008;1
4. Lussier A et al. Hylan in Clinical Practice. Jour of Clin Rheum 1996; 23::9-11
5. Data on File. Genzyme Corporation.
6. Chevalier X et al. Ann Rheum Dis 2007;66(Suppl II):494.